Compare ETSY & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ETSY | DFTX |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 5.9B |
| IPO Year | 2015 | 2020 |
| Metric | ETSY | DFTX |
|---|---|---|
| Price | $76.26 | $37.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 30 | 18 |
| Target Price | ★ $88.33 | $71.65 |
| AVG Volume (30 Days) | ★ 2.8M | 2.3M |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $441,231,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.72 | N/A |
| P/E Ratio | $300.56 | ★ N/A |
| Revenue Growth | ★ 20.90 | N/A |
| 52 Week Low | $44.00 | $14.62 |
| 52 Week High | $87.97 | $49.70 |
| Indicator | ETSY | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.04 | 48.36 |
| Support Level | $71.38 | $36.11 |
| Resistance Level | $87.13 | $44.60 |
| Average True Range (ATR) | 3.01 | 1.87 |
| MACD | 0.82 | -0.04 |
| Stochastic Oscillator | 97.36 | 61.85 |
Founded in 2005, Etsy operates a leading global marketplace, connecting roughly 87 million active buyers and 6 million sellers of unique, handmade, and vintage goods. In fiscal 2025, the firm generated $2.9 billion in revenue and almost $12 billion in gross merchandise sales. The firm monetizes its marketplace primarily through transaction fees and advertising, with core categories spanning homeware, jewelry, apparel, and craft supplies. The US drives 74% of sales, though its core geographic reach extends to the UK, Germany, Canada, and Australia.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.